


# THERE ARE AROUND 300,000 REASONS FOR CONSIDERING RIVOTRIL IN EPILEPSY



Rivotril is an important new benzodiazepine derivative for the treatment of *all* clinical forms of epileptic disorder. The majority of epileptic patients - there are about 300,000 in the UK - are maintained with several drugs, a considerable number of which exhibit severe side-effects and pose real problems in over-dosage.

That an anticonvulsant drug should be a benzodiazepine with low toxicity,<sup>1</sup> be remarkably free from serious side-effects,<sup>2,3,4,5</sup> have a rapid onset of action<sup>5</sup> and be compatible with other anticonvulsants<sup>3,4</sup> constitutes a major breakthrough.

Rivotril is such a drug.

- The effect of [Rivotril] on grand mal is remarkable . . . in the majority of patients the favourable effect was indisputable. ••<sup>3</sup>
- Clonazepam [Rivotril] is particularly effective in cases of petit mal, and the results of treatment are certainly comparable with those achieved with other currently-used anticonvulsant drugs. ••<sup>2</sup>


1. Arch. Neurol. (Chic), 1972, 27, 205
2. S. Afr. med. J., 1973, 47, 1683
3. Acta neurol. scand., 1973, 49 (Suppl. 53), 91
4. *ibid.*, 82
5. Develop. Med. Child Neurol., 1972, 14, 3
6. Epilepsia (Amst.), 1971, 12, 197



# RIVOTRIL

Anticonvulsant

Rivotril is the trade mark for pharmaceutical preparations containing clonazepam  
Further information is available on request  
Roche Products Limited, 15 Manchester Square, London W1M 6AP  
J733000



**Can a non-fluorinated steroid offer both  
fluorinated effectiveness and hydrocortisone safety?**

# *locoid*

**the non-fluorinated answer**

Fluorinated steroids often have to be prescribed in order to achieve an effective control of a skin disorder. Unfortunately, in many circumstances, this may result in an unacceptable level of side effects such as skin atrophy, telangiectasia and striae. Locoid meets the need for effective treatment yet has been shown to be as safe as hydrocortisone.

## **As effective as the fluorinated steroids.**

In an impressive series of double-blind trials<sup>1,2,4</sup> Locoid proved to be as successful as Triamcinolone Acetonide, Betamethasone-17-valerate and Fluocinolone Acetonide in the treatment of both Eczema and Psoriasis.

## **As safe as hydrocortisone**

Clinical experience confirms that Locoid, like hydrocortisone, is unlikely to cause side effects even when used on delicate skin areas such as the face.<sup>5</sup> Locoid does not contain fluorine and is metabolised into two naturally occurring substances, hydrocortisone and butyric acid.

# *locoid*

**the logical first choice -  
as effective as the fluorinated steroids  
yet as safe as hydrocortisone.**

Locoid is a trade mark for  
hydrocortisone-17-butyrate

1 Brit. J. Clin. Pract. (1973) 27177 2 Brit. J. Clin. Pract. (1972) 23263 3 Brit. J. Derm. (1970) 8393 4 Brit. J. Derm. (1973) 8883  
5 Brit. J. Derm. (1973) 89505

# VELOSEF

broad spectrum, bactericidal power  
in respiratory and urinary tract  
infections



**Composition:**  
 capsules 250mg  
 - 125mg  
 for reconstituted  
 single

side effects  
 in patients  
 have been reported

# VELOSEF




# Now paediatrics gets the Seward treatment.

At Seward, we believe that instruments for paediatric surgery are every bit as important as adult instruments.

That's why we spent a long time developing and perfecting our own paediatric range – and we're grateful for the co-operation of so many children's hospitals, paediatric departments and consultants.

Now the range is complete – 580 fine quality stainless steel instruments. Including many which have never before been modified for paediatric use. And some entirely new instruments developed in the Seward workshop.



We think our new range will fill a good many gaps in the field of paediatrics. And as always with Seward, we're geared to fill them fast.

 **seward** -the fast word in quality

A.J. Seward, UAC House, Blackfriars Road, London SE1 9UG.  
Telephone: 01-928 7444

A member of the Medical Division of UAC International

# In pituitary dwarfism

# CRESCORMON<sup>®</sup>

## human growth hormone

Crescormon is a highly purified preparation of human pituitary growth hormone thoroughly tested for homogeneity and potency.

Substitution therapy with Crescormon in patients suffering from GH deficiency leads to an acceleration of growth. The therapy is safe and no resistance to treatment has been reported.

Crescormon is standardized both by radio-immunological determination and by biological assay. Each vial contains 4 IU determined against IRP Growth Hormone (WHO).

#### Indications

Dwarfism due to decreased or failed secretion of pituitary growth hormone. The diagnosis should be verified before the preparation is administered by an investigation of the pituitary function.

#### Contraindication

Diabetes mellitus.

#### Precautions

In spite of rigorous requirements for the collection and careful control of the pituitary glands used in the preparation of Crescormon, the risk of transmitting hepatitis cannot be excluded. The risk may be considered extremely small, however, and no cases have as yet been reported.

#### Side Effects

In clinical trials Crescormon has elicited the formation of antibodies in low titre in a few patients, which, however, has not affected the growth rate. Otherwise no adverse reactions have been observed.

#### Dosage

The dosage is individual, but in general a dose of at least 0.5 IU per kg body weight per week, divided into two to three intramuscular injections, is recommended.

#### Administration

Crescormon should be injected intramuscularly. The solution for injection is prepared by adding 2 ml Sodium Chloride Injection to the lyophilized substance in the vial. A made-up solution should be used immediately after preparation.

#### Storage

Refrigerator (2-5°C).

#### Pack

Crescormon combined package of lyophilized sterile HGH 4 IU (about 2 mg) and Sodium Chloride Injection in an ampoule of 2 ml.

Product Licence No. 0022/0020

Crescormon<sup>®</sup> is manufactured by AB Kabi, Stockholm, Sweden, and is available in the U.K. only from:

**KabiVitrum Ltd**  
Bilton House, Uxbridge Road,  
Ealing, London W5 2TH.  
Telephone: 01-567 4717 or 01-579 1871

from whom further information can be obtained.

Outside U.K. information and supplies are available from the respective Kabi representative or directly from AB Kabi, Fack, S-104 25 Stockholm, Sweden.



Wellcome

- References
1. *Postgrad med J.* (1971) 47, Supplement (September) 7.
  2. *Brit med J.* (1972), 2, 673.
  3. *Clin Trials J.* (1972), 9/3, 9.

SEPTRIN contains trimethoprim and sulphamethoxazole. Full prescribing information is available on request. Wellcome Medical Division, The Wellcome Foundation Ltd., Berkhamsted, Herts.

# Feels right for Septrin

## b.d. in urinary infections


When clinical examination reveals urinary infection in children, experience increasingly indicates the need for the prompt, vigorous action of SEPTRIN Paediatric Suspension.

Has it proved top oral treatment in a British study of 23,491 urinary pathogen infections? SEPTRIN has been judged superior to ampicillin<sup>2,3</sup> and is now well established as a first-line treatment for urinary infections.

**SEPTRIN**  
TRADE MARK  
**Paediatric  
Suspension**

# PEDIATRIC RESEARCH

An International Journal of Clinical, Laboratory and  
Developmental Investigation



PUBLISHED MONTHLY BY THE WILLIAMS & WILKINS CO / BALTIMORE, MD. U.S.A.

Each month *PEDIATRIC RESEARCH* brings you a comprehensive selection of informative and significant articles covering the latest in both clinical and experimental findings.

*PEDIATRIC RESEARCH* is an official publication of the International Pediatric Research Foundation, Inc., and is sponsored by The American Pediatric Society; The European Society for Paediatric Research, and The Society for Pediatric Research.

*Published by The Williams & Wilkins Company  
Distributed in the United Kingdom by Baillière Tindall  
Inquiries and subscription orders should be addressed to:*

**Baillière Tindall**

7 & 8 Henrietta Street, Covent Garden  
London WC2E8QE England



# Monatsschrift für Kinder- heilkunde

Organ der Deutschen Gesellschaft für Kinderheilkunde

123. Band · Heft 1 · Januar 1975

#### Originalien

- D. Feist, M. Obladen, D. Beduhn Diagnostische und therapeutische Probleme der extrahepatischen Pfortaderstenose aus pädiatrischer Sicht (Diagnostic and Therapeutical Problems of Extrahepatic Portal Vein Stenosis) 1  
Gy. Kóteles, P. Kemény, K. Reich Familiäre infantile Achalasie. 3 Fälle bei Geschwistern einer Familie (Familial Infantile Achalasia in Three Siblings) 9

#### Fortbildung und Praxis

##### Übersichten

- E. Gladtko Arzneitherapie beim Neugeborenen und jungen Säugling (Drug Therapy in Newborns and Young Babies) 15  
K. J. Netter Besonderheiten des Arzneimittelstoffwechsels beim Neugeborenen und jungen Säugling (Drug Metabolism in Early Life) 17  
H. M. von Hattingberg Pharmakokinetische Besonderheiten beim Neugeborenen und jungen Säugling (Special Pharmacokinetic Aspects in Newborns and Young Infants) 23  
A. Windorfer, jr., D. Karitzky Über die Bedeutung der Albumin-Bilirubin-Bindung bei der medikamentösen Therapie im Neugeborenenalter (The Importance of the Albumin Bilirubin Binding in Drug Therapy in the Newborn) 27  
G. W. Kretzschmar Über den Einfluß des Cardiogreens auf die Albuminbindung des Bilirubins in der Neonatalperiode (The Influence of Cardiogreen on the Albumin Binding of Bilirubin in the Neonatal Period) 31  
F. Janssen Krankheiten durch Arzneimittel beim Neugeborenen (Diseases Caused by Drug Therapy in Newborn Babies) 34  
C. Simon Antibiotika beim Neugeborenen und jungen Säugling (Antibiotics in Newborns and Young Infants) 38

#### Aktuelle Fragen

- K. H. Schäfer Von der Deutschen Gesellschaft für Kinderheilkunde beschlossene Richtlinien für die Betreuung von Risikoneugeborenen 41

#### Buchbesprechungen 45

#### Tagesgeschichte 48


Indexed in Current Contents



Eine spanische Ausgabe dieser Zeitschrift erscheint bei  
Editorial Lectura y Estudio, S.A., Barcelona.

# Metabolic Aspects of Disease

Treatment of inborn errors has advanced our basic knowledge of disease. Metabolic problems are also a frequent consequence of disease.



Day-time variations in serum phenylalanine (triangles) and tyrosine (circles) in a phenylketonuric child having his first meal as usual at 07.45 hours or fasting until 11.45 hrs. Note the phenylalanine depressing effect of the breakfast (phenylalanine-restricted meal with Albumaid (R) (Güttler, Olesen & Wamberg—Kennedy Institute—Denmark in *Enzymopenic Anaemias, Lysosomes and other papers*, pages 149-158 E. & S. Livingstone.)

## PRECISION PRODUCTS:

Designed to meet the metabolic defect are called for.

Products more fundamental than enzymes.

Products more basic than protein.

Products which enable precise nutrition.

Products which succeed where cows' milk is a failure.

## PRECISION PRODUCTS FOR:

Phenylketonuria, Homocystinuria, Cystinosis, Maple Syrup Urine Disease, Hyperglycinaemia, Hyperprolinaemia, Arginine Succinic Urea, Histidinaemia, Tyrosinosis, Carbohydrate and Protein Intolerance, Malabsorptions, Cystic Fibrosis, Glycogen Storage Disease.

## MILNER SCIENTIFIC AND MEDICAL RESEARCH

Now maintains a world-wide interest in every aspect of metabolism in disease, and products are directly available in most countries.

*For further details please write to Sole U.K. Agents:*

**SCIENTIFIC HOSPITAL SUPPLIES LTD.  
38 QUEENSLAND STREET, LIVERPOOL 7**